International Money Azioni (NASDAQ: IMXI)

International Money (NASDAQ:IMXI) Azioni

INTERNATIONAL MONEY EXPRESS

IntL Money Express

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

International Money

International Money Express, Inc. - Common Stock

International Money Express Inc

Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $1.83 by 17.49 percent. This is a 7.5 percent increase over earnings of $2.00 per share from the same period last year. The company reported quarterly sales of $1.42 billion which beat the analyst consensus estimate of $1.37 billion by 3.63 percent. This is a 8.39 percent decrease over sales of $1.55 billion the same period last year.

Earnings

Earnings Beats

News

Regal Rexnord Q1 Adj. EPS $2.15 Beats $1.83 Estimate, Sales $1.42B Beat $1.37B Estimate

Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures from the report. 
The Details: Ford Motor reported quarterly earnings of 14 cents per share, which beat the analyst consensus estimate of two cents, but is down from earnings of 49 cents per share from the prior year&#8217;s quarter. Quarterly revenue came in at $37.42 billion, which beat the analyst consensus estimate of $36.2 billion and is down from revenue of $39.89 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
For the first quarter, Ford reported: 
<ul>
<li>Ford Pro generated $1.3 billion in EBIT with a margin of 8.6% on $15.2 billion in revenue. </li>
<li>Ford Model e reported a first-quarter EBIT loss of $849 million. </li>
<li>Ford Blue reported $96 million in EBIT, down from a year ago due to expected volume decline and adverse exchange. Segment revenue declined 3% to $21 billion.</li>
<li>Ford Credit reported first-quarter earnings before taxes (EBT) of $580 million, up significantly compared to a year ago. </li>
</ul>
&#8220;We are strengthening our underlying business with significantly better quality and our third straight quarter of year-over-year cost improvement, excluding the impact of tariffs," said Ford CEO Jim Farley. 
"Ford Pro, our largest competitive advantage, is off to a strong start to the year, gaining market share in the most profitable U.S. and European customer segment,&#8221; Farley added.
Outlook: Ford suspended its financial guidance, including full-year adjusted EBIT and adjusted free cash flow, due to tariff-related uncertainty.
F Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Ford Motor stock was down 2.46% after hours at $9.92 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

After-Hours Center

Movers

Ford Stock Hits The Brakes After Q1 Earnings, Suspends Guidance Due To 'Tariff-Related Uncertainty'

Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and&nbsp;Blackstone Credit&nbsp;&amp; Insurance for&nbsp;$295 million&nbsp;in cash.
The company will use the proceeds to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45189850/elanco-sells-royalty-and-milestone-rights-for-lotilaner-in-human-health-to-blackstone-accelerates-" rel="noreferrer noopener">by the end of 2025</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43951589/elanco-animals-outlook-lags-street-expectations-but-analyst-sees-time-for-elancos-commercial-investment-to-payoff" rel="noreferrer noopener">Elanco Animal's Outlook Lags Street Expectations, But Analyst Sees Time For Elanco's Commercial Investment To Payoff</a>
Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce interest expense by approximately&nbsp;$10 million, offset by the sale of approximately&nbsp;$10 million&nbsp;of royalties based on Elanco's initial 2025 guidance.
In 2019, Elanco exclusively licensed lotilaner to Tarsus Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) for exploration as a solution to several unmet human health needs.
In 2023, Xdemvy became the first lotilaner-based product approved for human use and the only FDA-approved medicine for Demodex&nbsp;blepharitis, a common eyelid disease in humans caused by&nbsp;Demodex&nbsp;mites.
The agreement applies to certain tiered royalties associated with Xdemvy's U.S. net sales from&nbsp;April 2025&nbsp;through&nbsp;August 2033&nbsp;and certain commercial milestones.
Elanco retains the rights to all royalty payments on net sales outside the U.S. and any future human applications of lotilaner beyond ophthalmic solutions.&nbsp;&nbsp;
Elanco Animal Health is scheduled to release its first quarter 2025 financial results on&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44731940/elanco-confirms-date-and-conference-call-for-first-quarter-2025-financial-results-announcement" rel="noreferrer noopener">Wednesday, May 7</a>.
Analysts expect adjusted earnings per share of 31 cents and sales of $1.21 billion, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
<h2 class="wp-block-heading">Elanco Health Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Elanco Animal Health, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Elanco Animal Health, the 200-day moving average sits at $12.34, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $9.75. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ELAN stock closer lower by 1.03% to $9.65 and TARS stock lower by 1.35% to $48.00 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45179007/becton-dickinson-vitals-drop-analysts-have-been-wrong-on-this-med-tech-stock-for-years" target="_blank" rel="noreferrer noopener">Becton Dickinson Vitals Drop: Analysts ‘Have Been Wrong' On This Med Tech Stock For Years</a></li>
</ul>
Photo by T Sxhneider via Shutterstock

Large Cap

Health Care

Trading Ideas

General

ELAN

TARS

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

As required by the Company Guide, the Company will submit a detailed plan by May 29, 2025, advising of actions it has taken or will take to regain compliance with the continued listing standards by the compliance deadline of October 29, 2026. If NYSE Regulation determines to accept the plan, the Company will be subject to periodic reviews, including quarterly monitoring for compliance. If the plan is not accepted, or the Company does not make progress under the plan during the plan period, NYSE may commence delisting proceedings. However, the Company is entitled to appeal a staff delisting determination in accordance with the Company Guide.

BURU

NUBURU Received NYSE Noncompliance Notice

Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $(0.05) by 880 percent. This is a 378.57 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $97.76 million which beat the analyst consensus estimate of $82.43 million by 18.60 percent. This is a 23.30 percent increase over sales of $79.29 million the same period last year.

Intrepid Potash Q1 Adj. EPS $0.39 Vs $(-0.14) YoY, Sales $97.76M Vs 79.2M YoY

Management

GTBP

GT Biopharma Appoints Michael Breen As CEO For Two-Year Term

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/b45206388/palantir-reports-q1-2025-revenue-growth-of-39-yy-u-s-revenue-growth-of-55-yy-raises-fy-2025-revenu">of the report</a>.
Q1 Earnings: Palantir reported first-quarter revenue of $883.86 million, beating <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $862.83 million. The company reported first-quarter adjusted earnings of 13 cents per share, in line with analyst estimates.
Palantir has now met or exceeded analyst estimates for revenue and earnings in seven straight quarters, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a> data.
Total revenue was up 39% year-over-year as U.S. revenue grew 55% year-over-year to $628 million. U.S. Commercial revenue grew 71% year-over-year to $255 million and U.S. Government revenue climbed 45% year-over-year to $373 million.
Palantir's customer count grew 39% year-over-year and 8% on a quarter-over-quarter basis. The company said it closed 139 deals worth over $1 million during the quarter and 51 deals worth at least $5 million. Palantir generated $310 million in cash from operations and $370 million in adjusted free cash flow in the quarter.&nbsp;
Palantir ended the quarter with $5.4 billion of cash, cash equivalents and short-term U.S. treasury securities.
&#8220;Our Rule of 40 score increased to&nbsp;83%&nbsp;in the last quarter, once again breaking the metric. We are in the middle of a tectonic shift in the adoption of our software,&#8221; said&nbsp;Alex Karp, co-founder and CEO of Palantir.
&#8220;We are delivering the operating system for the modern enterprise in the era of AI. Consequently, we are raising our full-year&nbsp;guidance&nbsp;for total revenue growth to&nbsp;36%&nbsp;and our&nbsp;guidance&nbsp;for U.S. commercial revenue growth to&nbsp;68%.&#8221;
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45202080/stocks-pause-gains-as-treasury-yields-rise-whats-driving-markets-monday">Stocks Pause Gains As Treasury Yields Rise: What&#8217;s Driving Markets Monday?</a>
Outlook: Palantir expects second-quarter revenue to be in the range of $934 million to $938 million versus estimates of $899.12 million.
The company also raised its full-year guidance. Palantir expects full-year 2025 revenue of $3.89 billion to $3.90 billion, up from prior guidance of $3.74 billion to $3.76 billion. Analysts were anticipating full-year revenue of $3.75 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Palantir raised guidance for full-year U.S. commercial revenue, full-year adjusted income from operations and adjusted free cash flow. The company now expects full-year adjusted free cash flow of $1.6 billion to $1.8 billion, up from prior guidance of $1.5 billion to $1.7 billion.
Finally, Palantir continued to guide for positive GAAP operating income and net income in each quarter of 2025.
&#8220;This is a level of surging and ferocious growth that would be spectacular for a company a tenth of our size. At this scale, however, our ascent is, we believe, unparalleled,&#8221; Karp said in a letter to shareholders. 
Palantir executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
PLTR Price Action: <a href="https://www.benzinga.com/quote/PLTR" target="_blank" rel="noreferrer noopener">Palantir shares </a>were up approximately 64% year-to-date heading into Monday&#8217;s report. The stock was down 9.23% in after-hours, trading at $112.35 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45203793/datadogs-ai-cloud-migration-expanding-product-adoption-drive-analyst-confidence-despite-growth-volatility-concerns">Datadog&#8217;s AI, Cloud Migration, Expanding Product Adoption Drive Analyst Confidence Despite Growth Volatility Concerns</a></li>
</ul>
Image: <a href="https://www.shutterstock.com/g/PoetraRH">Poetra.RH</a>/Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Palantir Technologies Q1 2025 Earnings Call &#x7C; $PLTR" width="500" height="281" src="https://www.youtube.com/embed/WgOqogXV_w4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Guidance

Tech

PLTR

Palantir Q1 Earnings: Revenue Beat, EPS In Line, Customer Count Up 39%, Company Raises Guidance Citing 'Surging And Ferocious Growth'

Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evolus.com%2Four-culture%2F&amp;esheet=54248377&amp;newsitemid=20250505216119&amp;lan=en-US&amp;anchor=Evolus%2C+Inc.&amp;index=1&amp;md5=d86edc3e18acb91ab674d69a87838519">Evolus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP.
Highlights of the new facility include:
<ul>
<li>Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly using the 3-month SOFR plus 5.00% per annum.</li>
<li>Improved Structure &amp; Financial Flexibility: Converted from an amortizing structure to a bullet maturity payment, with significantly reduced pre-payment fees, avoided any pre-payment fees from the existing facility, and additional consideration of 1% of the drawn value for the new facility, making it a cost-effective agreement.</li>
<li>Increased Capital Availability: Added $100 Million of discretionary incremental capacity with a senior secured term loan of up to $250 million in three tranches, with $150 million being drawn upon the execution of the agreement. At its discretion, Evolus may draw up to two additional tranches of $50 million each through December 31, 2026. These second and third tranches are available with no additional performance conditions or financial covenants.</li>
</ul>

EOLS

Evolus Replaces Existing $125M Credit Agreement With New $250M Credit Facility With Funds Managed By Pharmakon Advisors

TG Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">consensus of 17 cents</a>.
The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190356/tg-therapeutics-reports-first-quarter-2025-financial-results-and-raises-briumvi-full-year-revenue-" rel="noreferrer noopener">consensus of $118.43 million</a>.
Michael S. Weiss, the Company&#8217;s Chairman and Chief Executive Officer, stated, &#8220;2025 is off to a strong start, and I&#8217;m incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI&#8217;s $119.7 million in U.S. net sales, demonstrates the growing confidence in our treatment and the increasing adoption by healthcare providers. This momentum, combined with the positive feedback we&#8217;re hearing from both patients and clinicians, reinforces our belief that we can achieve our long-term goal of BRIUMVI becoming the number one prescribed anti-CD20 treatment based on dynamic market share.&#8221; 
&#8220;In addition to our ongoing BRIUMVI commercialization efforts, we are continuing to invest in innovation, including simplifying the BRIUMVI treatment regimen, advancing subcutaneous BRIUMVI, and developing azer-cel for progressive MS,&#8221; Weiss added.
Briumvi sales reached $119.7 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44439613/stock-of-the-day-tg-therapeutics-breaks-out-may-head-higher" rel="noreferrer noopener">Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher</a>
The company said it presented five-year data from the open-label extension study of the ULTIMATE I &amp; II Phase 3 trials evaluating Briumvi in adult patients with relapsing forms of multiple sclerosis (RMS).
<ul>
<li>The data demonstrated that 92% of patients were free from disability progression after five years of treatment, an annualized relapse rate of 0.02 during year 5 of treatment (equivalent to one relapse occurring every fifty years of patient treatment), and an overall safety profile that remained consistent, with no new safety signals emerging over 5 years of continuous treatment and no observed cases of progressive multifocal leukoencephalopathy (PML) to date.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147899/biogen-beats-q1-earnings-expectations-as-two-newcomer-drug-sales-spike-avoids-tariff-impact" rel="noreferrer noopener">Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact</a>
The company also presented data from the ENHANCE Phase 3b trial evaluating alternative dosing strategies for Briumvi in patients with RMS, which demonstrated that:
<ul>
<li>A single 600 mg Briumvi infusion on Day 1 was well tolerated in individuals with RMS regardless of prior treatment or B-cell depletion status.</li>
<li>Rapid 30-minute Briumvi infusions were well tolerated in patients with RMS.</li>
</ul>
Guidance: TG Therapeutics raised Briumvi&#8217;s U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance.
<ul>
<li>The company raised the total global revenue target to $575 million from prior guidance of $540 million.</li>
</ul>
Briumvi&#8217;s U.S. net product revenue is expected to be $135 million in the second quarter of 2025.
Price Action: TGTX stock was down 13.2% at $37.68 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45199066/berkshire-hathaway-stock-falls-following-buffetts-retirement-as-ceo" target="_blank" rel="noreferrer noopener">Berkshire Hathaway Stock Falls Following Buffett&#8217;s Retirement As CEO</a></li>
</ul>
Photo: Shutterstock

Biotech

TGTX

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

Offerings

MAIA

MAIA Biotechnology Announces $1.08M Private Placement Of 719,999 Shares At $1.50/Share

Valaris Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) ("Valaris" or the "Company") announced today that it has agreed to sell jackup VALARIS 247 to BW Energy ("BWE") for cash proceeds of approximately $108 million. This sale is expected to close in the second half of 2025, subject to customary closing conditions. As part of the sales agreement, BWE will be restricted from using the rig outside of BWE-owned or affiliated properties for the rig's expected remaining useful life.

Valaris Agrees To Sell Jackup VALARIS 247 To BW Energy For Cash Proceeds Of About $108M

Solesence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLSN#NASDAQ">SLSN</a>) reported $14.63 million in sales this quarter. This is a 48.21 percent increase over sales of $9.87 million the same period last year.

SLSN

Solesence Q1 EPS $0.00 Down From $0.02 YoY; Sales $14.63M Up From $9.87M YoY

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) raises FY2025 Adj EPS guidance from $3.05-$3.20 to $3.15-$3.30 vs $3.15 analyst estimate..

New Jersey Resources Raises FY2025 Adj EPS Guidance from $3.05-$3.20 to $3.15-$3.30 vs $3.15 Est

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) reported quarterly earnings of $1.78 per share which beat the analyst consensus estimate of $1.62 by 9.88 percent. This is a 26.24 percent increase over earnings of $1.41 per share from the same period last year. The company reported quarterly sales of $913.03 million which beat the analyst consensus estimate of $732.00 million by 24.73 percent. This is a 38.78 percent increase over sales of $657.91 million the same period last year.

New Jersey Resources Q2 Adj. EPS $1.78 Beats $1.62 Estimate, Sales $913.03M Beat $732.00M Estimate

Accel Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is unchanged from the same period last year. The company reported quarterly sales of $323.91 million which beat the analyst consensus estimate of $318.75 million by 1.62 percent. This is a 7.32 percent increase over sales of $301.82 million the same period last year.

ACEL

Accel Entertainment Q1 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $323.91M Beat $318.75M Estimate

Dividends

Cabot Corporation Board Increases Dividend From $0.43 to $0.45

JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 180.95 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $776.00 million which beat the analyst consensus estimate of $767.97 million by 1.05 percent. This is a 19.09 percent decrease over sales of $959.10 million the same period last year.

JELD

JELD-WEN Holding Q1 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $776.00M Beat $767.97M Estimate

Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) affirms FY2025 Adj EPS guidance from $3.95-$4.15 to $3.95-$4.15 vs $4.06 analyst estimate. Raises FY2025 sales outlook from $2.85 billion-$2.90 billion to $2.87 billion-$2.92 billion vs $2.88 billion estimate.

BFAM

Bright Horizons Family Affirms FY2025 Adj EPS Guidance of $3.95-$4.15 vs $4.06 Est; Raises FY2025 Sales Guidance from $2.85B-$2.90B to $2.87B-$2.92B vs $2.88B Est

Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 61.54 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $323.34 million which beat the analyst consensus estimate of $321.00 million by 0.73 percent. This is a 3.28 percent increase over sales of $313.07 million the same period last year.

CRD/A

Crawford Q1 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $323.34M Beat $321.00M Estimate

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) lowers FY2025 sales outlook from $302.00 million-$307.00 million to $297.50 million-$303.50 million vs $304.62 million estimate.

Comments

International Money

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO